Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Liquid biopsy may help guide treatment decisions for advanced solid tumours

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.16
Views: 1614
Rating:

Prof Philip Mack - University of California Davis, Davis, USA

Dr Mack speaks with ecancertv at ASCO 2016 about the use of liquid biopsy samples to guide treatment of solid tumours.

With blood samples from more than 15,000 patients and 50 tumour types, making this the largest study of its type, Dr Mack describes circulating DNA (ctDNA) as a way of monitoring patient response and tumour resistance over time, in a minimally invasive fashion.

While he acknowledges the importance of solid tumour biopsy as a key part of diagnosis and clinical practice, Dr Mack advocates integration of ctDNA assays for more reflexive practice.

Watch the press conference and read the news story for more. 

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation